A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses via Oral Administration to Healthy Participants

Trial Identifier: D9440C00001
Sponsor: AstraZeneca
Collaborator:
Parexel
NCTID:: NCT06122714
Start Date: November 2023
Primary Completion Date: October 2024
Study Completion Date: October 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Glendale, CA, US, 91206
US, MD Brooklyn, MD, US, 21225